Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions

Multiple Sclerosis and Related Disorders

Volumn 5, Issue , 2016, Pages 97-104

  Comi, Giancarlo ^a   Freedman, Mark S ^b   Kappos, Ludwig ^c   Olsson, Tomas P ^d   Miller, Aaron E ^e   Wolinsky, Jerry S ^f   O'Connor, Paul W ^g   Benamor, Myriam ^h   Dukovic, Deborah ^h   Truffinet, Philippe ^h   Leist, Thomas P ⁱ  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h SANOFI   (France)

ⁱ THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Clinical trials; Multiple sclerosis; Relapsing remitting multiple sclerosis; Teriflunomidem Safety analysis

Indexed keywords

ALANINE AMINOTRANSFERASE; PLACEBO; TERIFLUNOMIDE; CROTONIC ACID DERIVATIVE; IMMUNOLOGIC FACTOR; TOLUIDINE DERIVATIVE;

ABDOMINAL PAIN; APPENDICITIS; ARTICLE; DIARRHEA; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROENTERITIS; HAIR THINNING; HEADACHE; HUMAN; INCIDENCE; INFLUENZA; MULTIPLE SCLEROSIS; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; PNEUMONIA; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; ADOLESCENT; ADULT; DOUBLE BLIND PROCEDURE; FEMALE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CROTONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOLUIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84960489597     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2015.11.006     Document Type: Article

References (18)

1. Bar-Or, A., Freedman, M.S., Kremenchutzky, M., et al., 2013. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology 81, 552-558 [PubMed: 23851964].
2. Bar-Or, A., Pachner, A., Menguy-Vacheron, F., Kaplan, J., Wiendl, H., 2014. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 74, 659-674 [PubMed: 24740824].
3. Bar-Or, A., Wiendl, H., Miller, B., et al., 2015. Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. Neurol. Neu-roimmunol. Neuroinflamm. 2, e70. http://dx.doi.org/10.1212/NXI.0000000000000070.
4. Chambers, C.D., Johnson, D.L., Robinson, L.K., et al., 2010. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 62, 1494-1503 [PubMed: 20131283].
5. Confavreux, C., O'Connor, P., Comi, G., et al., 2014. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 13, 247-256 [PubMed: 24461574].
6. Confavreux, C., Li, D.K., Freedman, M.S., et al., 2012. Long-term follow-up ofa phase 2 study of oral teriflunomide in relapsing multiple sclerosis: Safety and efficacy results up to 8.5 years. Mult. Scler. 18, 1278-1289 [PubMed: 22307384].
7. Davenport, L., Czich, A., Turpault, S., 2013. Teriflunomide: no effects on sperm DNA. Mult. Scler. J. 19 (559-573), P1187.
8. Emery, P., Breedveld, F.C., Lemmel, E.M., et al., 2000. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39, 655-665 [PubMed: 10888712].
9. Freedman, M., Confavreux, C., Comi, C., et al., 2012. Hair thinning associated with teriflunomide therapy is manageable. In: Proceedings of the Fourth Cooperative Meeting of CMSC and ACTRIMS. San Diego, CA, USA.
10. Garcia-Enguidanos, A., Calle, M.E., Valero, J., Luna, S., Dominguez-Rojas, V., 2002. Risk factors in miscarriage: a review. Eur. J. Obs. Gynecol. Reprod. Biol. 102, 111-119 [PubMed: 11950476].
11. Gold, R., Wolinsky, J.S., 2011. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol. Scand. 124, 75-84 [PubMed: 20880295].
12. Kieseier, B.C., Benamor, M., 2014. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol. Ther. 3, 133-138.
13. Miller, A.E., Wolinsky, J.S., Kappos, L., et al., 2014. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 13, 977-986 [PubMed: 25192851].
14. O'Connor, P., Wolinsky, J.S., Confavreux, C., et al., 2011. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New. Engl. J. Med. 365, 1293-1303 [PubMed: 21991951].
15. O'Connor, P.W., Li, D., Freedman, M.S., et al., 2006. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66, 894-900 [PubMed: 16567708].
16. Smolen, J.S., Kalden, J.R., Scott, D.L., et al., 1999. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353, 259-266 [PubMed: 9929017].
17. Strand, V., Cohen, S., Schiff, M., et al., 1999. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide rheumatoid arthritis investigators group. Arch. Intern Med. 159, 2542-2550 [PubMed: 10573044].
18. Wolinsky, J.S., Narayana, P.A., Nelson, F., et al., 2013. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult. Scler. 19, 1310-1319 [PubMed: 23447359].